

Home / Citybiznews / Health/Biotech /

Get Email Newsletter RSS Feeds Text - +

MORE TOPICS:

## With Emory's Raymond Schinazi on Board, Gliknik Tops \$5.5M with Latest Raise - cbl

Posted September 6, 2011

Sign in to connect with your friends on Citybizlist



Insightful Unique Not For Me

Share Email this Article

By **Brian Wolak**

ATLANTA -- **Gliknik** has raised **\$2.04 million** from a \$2.32 million offering, adding to **\$3.5 million** in equity financing for the Baltimore-based biotech company since last year.



**Raymond Schinazi**

Gliknik is also the recipient of more than **\$1 million** of grant funding from

### We Recommend...

**Coca-Cola Exec Dominique Reiniche Sells \$3.5M in Company Shares - cbl**

**Home Depot's CEO, 11 Major Companies And America's Job Crisis: Part II**



the federal Qualified Therapeutic Discovery Project (QTDP), a U.S. Army subcontract through the Maryland Proof of Concept Alliance, and a State of Maryland Department of Business & Economic Development (DBED) Translational Research Award.

Having grown out of research by **Dr. Scott Strome**, professor of Otorhinolaryngology-Head & Neck Surgery at the University of Maryland School of Medicine in Baltimore, Gliknik develops drugs to treat autoimmune diseases and cancer through modulation of the immune system.

**Dr. David S. Block**, president and chief executive officer, is named in a regulatory filing disclosing the capital raise along with **Elizabeth Block** and directors **Joseph Klein, III**, of Stevenson, Md.-based **Gauss Capital Advisors LLC**; and **Raymond Schinazi, PhD**, Professor of Biochemical Pharmacology at Emory University, Atlanta.

Dr. Block previously held senior positions at DuPont Merck and **DuPont Pharmaceuticals**. Earlier he was chief operating officer of Celera Genomics. He also founded and ran Ruxton Pharmaceuticals, Inc., a venture-backed start-up.

Lawrenceville, Ga.-based **Trestle Point** received \$15,000 in finder's fees expenses along with \$15,000 in warrants for series A-3 preferred shares.

**SEC Filing:** <http://tinyurl.com/3ss9e8h>

#### **Bios:**

#### **Joseph R. Klein, III**

Joseph R. Klein, III serves as managing director of Gauss Capital Advisors LLC, which he founded. He has been a partner of Red Abbey Venture Partners, LLC since September 2003. He

**The Coca-Cola Company and Coca-Cola Enterprises to Merge in \$15B Deal**

**IntelliOne Closes on \$3.8M Round With Genuity Capital, Gets New CEO in David Winters - CBL**

**MaxPoint Interactive Appoints Cate Carley as Vice President, Agency Sales**

**Cleantech Company MyCelx Raises \$1.5M - cbl**

Powered by 

**CONTRIBUTE TO CITYBIZLIST  
SHARE YOUR NEWS ➔**

served as a venture partner of MPM Capital from September 2001 to September 2002. From June 1999 to September 2000, he served as the vice president of Strategy for Medical Manager Corp., until its merger with WebMD. From June 1998 to June 1999, Klein served as health care investment analyst at Edgemont Asset Management Inc. From 1995 to 1998, he served as a portfolio manager and securities analyst of T. Rowe Price Health Sciences Fund Inc. From 1989 to 1998, Klein served as vice president, health care portfolio manager and securities analyst for T. Rowe Price Associates Inc. and The Kaufmann Fund, Inc. He has also been director of ISIS Pharmaceuticals Inc., Savient Pharmaceuticals Inc., Keel Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., PDL BioPharma, Inc., Cogenics, Inc., NPS Pharmaceuticals Inc., Guilford Pharmaceuticals Inc., Clinical Data Inc., and OSI Pharmaceuticals Inc.

### **Raymond F. Schinazi, PhD**

Dr. Schinazi is the founder of several successful biotechnology companies; including Pharmasset Inc. (VRUS), Triangle Pharmaceuticals (VIRS; acquired by Gilead), Idenix Pharmaceuticals (IDIX, 56% acquired by Novartis), and most recently RFS Pharma, LLC. He is best known for his innovative and pioneering work on several antiviral drugs many of which are approved by the FDA. His inventions now sell more than US\$2 billion per year and more than 94% of the HIV infected individuals take at least one of the drugs he invented.

Dr. Schinazi is currently the Francis Winship Walters Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology at Emory University in Atlanta. He received his Ph.D. in Chemistry in 1976 and an Honorary D.Sc. in 2006 from Bath University, England, and completed post-doctoral training in Pharmacology at Yale University and Virology at Emory University. He has published more than 400 papers and seven books, and has more than 80 US patents. Dr. Schinazi has received many honors, including the Georgia Biomedical Industry Growth Award, Hepatitis B Foundation Bruce Witte Annual Distinguished Award and the Russian Kalinka Award, and was named by the Ewing Marion Kauffman Foundation 'Top Innovators in America'.

**Also at *citybizlist*, see:**

**Gliknik Launches New Round with \$850K - cbl**

To find out more about the company in this article and to see if you have business connections, click below :

 **Gliknik**

blog comments powered by **Disqus**

What people are saying about Citybizlist

Sign-in to connect with your friends on Citybizlist



